

ASX Announcement

30 August 2024

Appointment of Peter Hall as Non-Executive Director

Sydney, Australia – 30 August 2024: Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) refers to the announcement on 15 July 2024 regarding the appointment of Peter Hall as Non-Executive Director.

Peter has advised that, due to unforeseen personal family issues that require his immediate attention, he has reluctantly delayed joining the board of OncoSil until 1 October 2024.

Peter holds approximately 4% of OncoSil issued capital and intends to be an active director helping OncoSil realise the enormous potential that the Board envisages in the treatment of pancreatic cancer.

Peter Hall said: “Mahatma Gandhi once said that the difference between nothing and something is infinite. OncoSil is something. It offers a treatment which has the potential to impact the lives of the hundreds of thousands of people who contract pancreatic cancer and their families and loved ones.

I wish to do my very best to help turn this potential into a reality and regard it as a very serious responsibility and duty.

I am very grateful for the board of OncoSil granting me a month to deal with two serious family issues. Once completed, I will be able to focus my attention fully on developing OncoSil.”

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Christian Dal Cin CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699
--	--	---

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References: 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>